Skip to Content
Rule

New Animal Drugs; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin

Action

Final Rule.

Summary

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the withdrawal of approval of four new animal drug applications (NADAs) at the sponsor's request because the products are no longer manufactured or marketed.

 

Table of Contents Back to Top

Tables Back to Top

DATES: Back to Top

This rule is effective September 20, 2012.

FOR FURTHER INFORMATION CONTACT: Back to Top

David Alterman, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855; 240-453-6843; email: david.alterman@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Back to Top

The sponsors of the four approved NADAs listed in table 1 of this document have requested that FDA withdraw approval because the products are no longer manufactured or marketed:

Table 1—Withdrawal of Approval Requests Back to Top
NADA No. Trade name (drug) Applicant Citation in 21 CFR
030-525 NUMORPHAN (oxymorphone hydrochloride) Injection Endo Pharmaceuticals Inc., 100 Painters Dr., Chadds Ford, PA 19317 522.1642
035-825 NARCAN (naloxone hydrochloride) Injection Endo Pharmaceuticals Inc., 100 Painters Dr., Chadds Ford, PA 19317 522.1462
046-822 VETOCIN (oxytocin) Injection United Vaccines, A Harlan Sprague Dawley, Inc., Co., P.O. Box 4220, Madison, WI 53711 522.1680
103-090 CHORTROPIN (chorionic gonadotropin) Injection United Vaccines, A Harlan Sprague Dawley, Inc., Co., P.O. Box 4220, Madison, WI 53711 522.1081

Elsewhere in this issue of the Federal Register, FDA gave notice that approval of NADAs 030-525, 035-825, 046-822, and 103-090, and all supplements and amendments thereto, is withdrawn, effective September 20, 2012. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these voluntary withdrawals of approval.

Following these withdrawals of approval, Endo Pharmaceuticals Inc. and United Vaccines, A Harlan Sprague Dawley, Inc., Co., will no longer be the sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for these firms.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

List of Subjects Back to Top

Therefore, under the Federal Food, Drug, and Cosmetic Act and under the authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:

begin regulatory text

PART 510—NEW ANIMAL DRUGS Back to Top

1.The authority citation for 21 CFR part 510 continues to read as follows:

Authority:

21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

§ 510.600 [Amended]

2.In § 510.600, in the table in paragraph (c)(1), remove the entries for “Endo Pharmaceuticals Inc.” and “United Vaccines, A Harlan Sprague Dawley, Inc., Co.”; and in the table in paragraph (c)(2), remove the entries for “058639” and “060951”.

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS Back to Top

3.The authority citation for 21 CFR part 522 continues to read as follows:

Authority:

21 U.S.C. 360b.

§ 522.1081 [Amended]

4.In § 522.1081, remove and reserve paragraph (b)(2).

§ 522.1462 [Removed]

5.Remove § 522.1462.

§ 522.1642 [Removed]

6.Remove § 522.1642.

§ 522.1680 [Amended]

7.In § 522.1680, in paragraph (b), remove “058639,”.

end regulatory text

Dated: September 5, 2012.

Bernadette Dunham,

Director, Center for Veterinary Medicine.

[FR Doc. 2012-22196 Filed 9-7-12; 8:45 am]

BILLING CODE 4160-01-P

Site Feedback